share_log

Otonomy (NASDAQ:OTIC) Coverage Initiated at StockNews.com

Otonomy (NASDAQ:OTIC) Coverage Initiated at StockNews.com

Otonomy（纳斯达克股票代码：OTIC）的报道始于 StockNews.com
Financial News Live ·  2022/12/28 01:31

StockNews.com initiated coverage on shares of Otonomy (NASDAQ:OTIC – Get Rating) in a research report sent to investors on Saturday. The brokerage issued a hold rating on the biopharmaceutical company's stock.

StockNews.com开始报道以下公司的股票 Otonomy（纳斯达克股票代码：OTIC — 获取评级） 在周六发给投资者的研究报告中。该经纪公司对这家生物制药公司的股票发布了持有评级。

Separately, Piper Sandler cut shares of Otonomy from an overweight rating to a neutral rating and cut their price objective for the company from $3.00 to $0.50 in a report on Thursday, October 13th.

另外，派珀·桑德勒在10月13日星期四的一份报告中将Otonomy的股票从增持评级下调至中性评级，并将该公司的目标价格从3.00美元下调至0.50美元。

Get
获取
Otonomy
自治学
alerts:
警报：

Otonomy Price Performance

Otonomy 价格表现

Shares of Otonomy stock opened at $0.07 on Friday. The firm has a fifty day moving average price of $0.11 and a 200 day moving average price of $0.66. Otonomy has a 1 year low of $0.06 and a 1 year high of $2.59. The stock has a market cap of $4.23 million, a PE ratio of -0.10 and a beta of 1.31.

周五，Otonomy股票开盘价为0.07美元。该公司的五十天移动平均线价格为0.11美元，200天移动平均线价格为0.66美元。Otonomy创下1年低点0.06美元，1年高点2.59美元。该股的市值为423万美元，市盈率为-0.10，beta值为1.31。

Institutional Trading of Otonomy

自主学的机构交易

Several institutional investors have recently modified their holdings of OTIC. Two Sigma Investments LP grew its position in shares of Otonomy by 129.2% in the third quarter. Two Sigma Investments LP now owns 142,183 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 80,153 shares during the period. Requisite Capital Management LLC acquired a new position in Otonomy during the third quarter worth about $44,000. State Street Corp boosted its position in Otonomy by 5.1% during the first quarter. State Street Corp now owns 182,239 shares of the biopharmaceutical company's stock worth $437,000 after acquiring an additional 8,839 shares during the last quarter. Lynx1 Capital Management LP boosted its position in Otonomy by 7,609.6% during the third quarter. Lynx1 Capital Management LP now owns 2,312,880 shares of the biopharmaceutical company's stock worth $682,000 after acquiring an additional 2,282,880 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in Otonomy during the third quarter worth about $1,621,000. Institutional investors and hedge funds own 41.23% of the company's stock.
一些机构投资者最近修改了他们持有的OTIC。Two Sigma Investments LP在第三季度将其在Otonomy股票中的头寸增加了129.2％。Two Sigma Investments LP在此期间又购买了80,153股股票后，现在拥有这家生物制药公司142,183股股票，价值42,000美元。Requiend Capital Management LLC在第三季度收购了Otonomy的新职位，价值约44,000美元。State Street Corp在第一季度将其在Otonomy中的地位提高了5.1％。State Street Corp在上个季度又收购了8,839股股票后，现在拥有这家生物制药公司的182,239股股票，价值43.7万美元。Lynx1 Capital Management LP在第三季度将其在Otonomy的地位提高了7,609.6％。Lynx1 Capital Management LP在上个季度又收购了2,282,880股股票后，现在拥有这家生物制药公司的2312,880股股票，价值68.2万美元。最后，Point72 Asset Management L.P. 在第三季度收购了Otonomy的新职位，价值约16.1万美元。机构投资者和对冲基金拥有该公司41.23％的股票。

Otonomy Company Profile

Otonomy 公司简介

(Get Rating)

（获取评分）

Otonomy, Inc, a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties.

Otonomy, Inc是一家生物制药公司，在美国开发神经病学疗法。该公司提供 OTO-313，一种持续暴露的N-甲基-D-天冬氨酸受体拮抗剂加环素配方，目前正在进行治疗耳鸣的II期临床试验；以及 OTO-413，一种大脑源性神经营养因子的持续暴露配方，正在进行用于修复耳蜗突触病和治疗噪音中言语听力障碍的IIa期临床试验。

Featured Articles

精选文章

  • Get a free copy of the StockNews.com research report on Otonomy (OTIC)
  • 3 Industrial Stocks to Help Build Your 2023 Watchlist
  • The Institutions Choose CarMax Over Carvana, Should You?
  • Heatmap in Trading: How to Learn What Market Depth Hides
  • Micron Technology Sees Chip Recovery by the End of 2023
  • Three Healthcare Penny Stocks to Watch In The New Year
  • 免费获取 StockNews.com 关于自主学的研究报告（OTIC）的副本
  • 3 只工业股将帮助您建立 2023 年关注名单
  • 机构选择 CarMax 而不是 Carvana，你应该吗？
  • 交易热图：如何了解市场深度隐藏了什么
  • 美光科技预计芯片将在2023年底之前复苏
  • 新年值得关注的三只医疗保健细价股

Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.

接收 Otonomy Daily 的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Otonomy及相关公司的最新新闻和分析师评级的简明每日摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发